We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+24.97%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$18.7M
Cap. Flow
-$61M
Cap. Flow %
-14.23%
Top 10 Hldgs %
55.8%
Holding
50
New
11
Increased
13
Reduced
18
Closed
8

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$23.4M
2
DXCM icon
DexCom
DXCM
+$9.91M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.57M
4
BSX icon
Boston Scientific
BSX
+$7.88M
5
SEM
Select Medical
SEM
+$6.94M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$34.3M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$20M
3
FOLD
Amicus Therapeutics
FOLD
+$12.6M
4
ARGX icon
argenx
ARGX
+$12.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.02%
2 Industrials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$39.8M 9.29%
1,150,000
-623,649
-35% -$20M
MGTX icon
2
MeiraGTx Holdings
MGTX
$1.09B
$33.7M 7.85%
4,089,509
-497,914
-11% -$3.94M
ADCT icon
3
ADC Therapeutics
ADCT
$146M
$29.9M 6.97%
7,472,303
-2,995,468
-29% -$9.44M
KURA icon
4
Kura Oncology
KURA
$922M
$24.4M 5.69%
2,758,516
-422,668
-13% -$3.01M
ISRG icon
5
Intuitive Surgical
ISRG
$121B
$21.8M 5.08%
+48,711
New +$23.4M
JANX icon
6
Janux Therapeutics
JANX
$935M
$21.1M 4.93%
865,350
+11,446
+1% +$279K
ROIV icon
7
Roivant Sciences
ROIV
$25.2B
$20.2M 4.71%
1,335,500
-473,039
-26% -$5.86M
ICLR icon
8
Icon
ICLR
$12.8B
$19.2M 4.47%
109,500
+10,942
+11% +$1.83M
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.84B
$15.4M 3.6%
1,003,400
-76,273
-7% -$998K
BBIO icon
10
BridgeBio Pharma
BBIO
$16.5B
$13.7M 3.2%
264,500
-208,187
-44% -$10.2M
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$8.86B
$13.7M 3.19%
328,684
+30,561
+10% +$977K
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
$13.5M 3.14%
1,709,533
-1,770,511
-51% -$12.6M
DXCM icon
13
DexCom
DXCM
$27.6B
$13.1M 3.06%
195,217
+125,217
+179% +$9.91M
STTK icon
14
Shattuck Labs
STTK
$710M
$13M 3.04%
5,451,195
-1,187,740
-18% -$1.45M
ZYME icon
15
Zymeworks
ZYME
$1.68B
$12.8M 2.99%
749,611
-560,293
-43% -$8.02M
CON
16
Concentra Group Holdings
CON
$4.04B
$12.8M 2.98%
610,000
+297,895
+95% +$6.35M
CORT icon
17
CALL
Corcept Therapeutics
CORT
$10.2B
$12.3M 2.86%
+147,800
New +$10.7M
IMVT icon
18
Immunovant
IMVT
$8.09B
$11.3M 2.63%
698,472
+219,072
+46% +$3.55M
SEM
19
DELISTED
Select Medical
SEM
$11.2M 2.62%
874,915
+521,095
+147% +$6.94M
BHVN icon
20
Biohaven
BHVN
$2.16B
$9.01M 2.1%
600,000
+60,929
+11% +$887K
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$121B
$8.03M 1.87%
+20,500
New +$8.57M
BSX icon
22
Boston Scientific
BSX
$65.8B
$7.43M 1.73%
+76,100
New +$7.88M
CDNA icon
23
CareDx
CDNA
$1.92B
$7.33M 1.71%
504,030
+201,222
+66% +$2.87M
ACHC icon
24
Acadia Healthcare
ACHC
$3.17B
$6.19M 1.44%
250,000
+38,184
+18% +$852K
TECX
25
Tectonic Therapeutic
TECX
$573M
$5.95M 1.39%
379,254
-62,802
-14% -$1.3M
1
2

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q3 2025 Portfolio in Review

As of Q3 2025, Prosight Management held 50 positions worth $429M, up 4.6% from $410M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Prosight Management withdrew a net $61M in Q3 2025, closing 8 positions and reducing 18 holdings. Its most notable exit was UnitedHealth, an estimated $34.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier, followed by Industrials.

Against the trend, Prosight Management opened a new position in Intuitive Surgical worth $21.8M.

  • Prosight Management's largest Q3 2025 buy was Intuitive Surgical: 48,711 shares worth $21.8M.
  • Prosight Management added most to DexCom in Q3 2025, an estimated $9.91M increase.
  • Prosight Management's biggest Q3 2025 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $20M.
  • Prosight Management fully exited UnitedHealth in Q3 2025, selling an estimated $34.3M.
  • Prosight Management's ten largest holdings make up 56% of its $429M portfolio in Q3 2025.
  • Prosight Management opened 11 new positions and closed 8 in Q3 2025.
  • Prosight Management's portfolio value rose 4.6% quarter-over-quarter to $429M.

Based on Prosight Management's 13F filing for Q3 2025, filed 14 Nov 2025.